RWJ 68023

Drug Profile

RWJ 68023

Alternative Names: Motilin receptor antagonists - Johnson & Johnson; RWJ-68023

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Motilin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Dyspepsia; Irritable bowel syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Dyspepsia in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in USA (PO)
  • 11 Oct 2004 Phase-I clinical trials in Dyspepsia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top